1. Home
  2. REGCP vs IMNM Comparison

REGCP vs IMNM Comparison

Compare REGCP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regency Centers Corporation

REGCP

Regency Centers Corporation

N/A

Current Price

$23.43

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.24

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGCP
IMNM
Founded
N/A
2006
Country
United States
United States
Employees
500
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
REGCP
IMNM
Price
$23.43
$21.24
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.44
AVG Volume (30 Days)
N/A
3.0M
Earning Date
N/A
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,679,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.53
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$5.15
52 Week High
N/A
$25.30

Technical Indicators

Market Signals
Indicator
REGCP
IMNM
Relative Strength Index (RSI) 41.62 55.21
Support Level $23.04 $21.00
Resistance Level $23.50 $22.57
Average True Range (ATR) 0.16 1.47
MACD -0.03 -0.08
Stochastic Oscillator 45.68 36.90

Price Performance

Historical Comparison
REGCP
IMNM

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: